Dashboard
Manage Tickers

AUPHAurinia Pharmaceuticals Inc.

Nasdaq auriniapharma.com


$ 6.86 $ -0.39 (-5.37 %)    

Monday, 09-Sep-2024 15:59:56 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 455.25 $ 5.77 (1.29 %)
DIA $ 409.08 $ 4.58 (1.13 %)
SPY $ 546.60 $ 6.05 (1.12 %)
TLT $ 99.96 $ 0.43 (0.43 %)
GLD $ 231.58 $ 0.97 (0.42 %)
$ 6.87
$ 7.22
$ 6.86 x 400
-- x --
$ 6.79 - $ 7.25
$ 4.71 - $ 10.24
1,576,620
na
982.35M
$ 1.04
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-01-2024 06-30-2024 10-Q
2 05-02-2024 03-31-2024 10-Q
3 02-15-2024 12-31-2023 10-K
4 11-02-2023 09-30-2023 10-Q
5 08-03-2023 06-30-2023 10-Q
6 05-04-2023 03-31-2023 10-Q
7 02-28-2023 12-31-2022 10-K
8 11-03-2022 09-30-2022 10-Q
9 08-04-2022 06-30-2022 10-Q
10 05-10-2022 03-31-2022 10-Q
11 02-28-2022 12-31-2021 10-K
12 11-03-2021 09-30-2021 10-Q
13 08-05-2021 06-30-2021 10-Q
14 05-06-2021 03-31-2021 10-Q
15 02-24-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

cantor-fitzgerald-reiterates-overweight-on-aurinia-pharmaceuticals-maintains-10-price-target
Cantor Fitzgerald Reiterates Overweight on...
09/09/2024 15:19:13

Cantor Fitzgerald analyst Olivia Brayer reiterates Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Overweight and maintains $10...

hc-wainwright--co-reiterates-buy-on-aurinia-pharmaceuticals-maintains-13-price-target
HC Wainwright & Co. Reiterates Buy on Auri...
09/06/2024 09:38:57

HC Wainwright & Co. analyst Ed Arce reiterates Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Buy and maintains $13 price ...

aurinia-pharmaceuticals-narrows-2024-net-product-revenue-range-from-200m-220m-to-210m-220m
Aurinia Pharmaceuticals Narrows 2024 Net P...
08/01/2024 10:03:19

aurinia-pharmaceuticals-q2-2024-gaap-eps-001-inline-sales-57200m-beat-55055m-estimate
Aurinia Pharmaceuticals Q2 2024 GAAP EPS $...
08/01/2024 10:02:47

Aurinia Pharmaceuticals (NASDAQ:AUPH) reported quarterly earnings of $0.01 per share which met the analyst consensus estimate. ...

iljin-snt-co-ltd-announces-intention-to-vote-against-aurinia-pharmaceuticalss-revised-equity-incentive-plan-proposal
ILJIN SNT Co., Ltd Announces Intention To ...
06/07/2024 15:48:26

- Reuters

aurinia-pharmaceuticals-announced-an-oral-presentation-at-the-european-alliance-of-associations-for-rheumatology-2024-in-vienna-austria-june-12-15-which-includes-safety-and-efficacy-profile-of-lupkynis-for-people-with-lupus-nephritis
Aurinia Pharmaceuticals Announced An Oral ...
06/05/2024 10:02:08

aurinia-issues-letter-to-shareholders-in-response-to-letter-from-shareholder-lucien-selce-company-raises-concerns-surrounding-lucien-selces-lack-of-credibility
Aurinia Issues Letter To Shareholders In R...
06/04/2024 21:35:00

The Company recommends that shareholders review the recent report from proxy advisor Glass Lewis, which recommends shareholders...

aurinia-pharmaceuticals-shareholder-urges-fellow-shareholders-to-withhold-support-for-ceo-peter-greenleaf-says-removing-ceo-and-director-peter-greenleaf-from-the-co-would-pave-the-way-for-a-superior-board-and-strategy-that-would-rejuvenate-aurinia
Aurinia Pharmaceuticals Shareholder Urges ...
06/03/2024 12:33:20

analysis-showing-lupkynis-is-a-cost-effective-treatment-for-lupus-nephritis-presented-at-national-kidney-foundations-spring-clinical-meeting-2024
Analysis Showing LUPKYNIS Is A Cost-Effect...
05/14/2024 10:09:00

aurinia-reports-presentation-of-two-studies-at-the-annual-congress-of-clinical-rheumatology
Aurinia Reports Presentation Of Two Studie...
05/09/2024 10:12:59

The data reinforce previous findings on the safety and effectiveness of LUPKYNIS (voclosporin), a second generation calcineurin...

aurinia-pharmaceuticals-shareholder-urges-board-of-directors-to-take-action-to-enhance-shareholder-value-outlines-concerns-regarding-the-companys-current-strategy-and-board-composition-and-offers-superior-paths-to-improving-performance-and-market-penetration
Aurinia Pharmaceuticals Shareholder Urges ...
05/07/2024 13:18:04

Outlines Concerns Regarding the Company's Current Strategy and Board Composition and Offers Superior Paths to Improving Per...

aurinia-reiterates-2024-net-product-revenue-guidance-of-200m-220m
Aurinia Reiterates 2024 Net Product Revenu...
05/02/2024 10:03:59

aurinia-pharmaceuticals-q1-2024-gaap-eps-007-beats-014-estimate-sales-50300m-beat-47453m-estimate
Aurinia Pharmaceuticals Q1 2024 GAAP EPS $...
05/02/2024 10:01:03

Aurinia Pharmaceuticals (NASDAQ:AUPH) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate ...

aurinia-pharmaceuticals-announced-several-initiatives-to-improve-understanding-of-the-seriousness-of-lupus-nephritis-and-the-need-for-frequent-screening-and-appropriate-management
Aurinia Pharmaceuticals Announced Several ...
05/01/2024 10:19:10

fda-approves-updated-lupkynis-voclosporin-label-to-include-long-term-data-from-the-aurora-clinical-program
FDA Approves Updated LUPKYNIS (voclosporin...
04/30/2024 10:13:19

The updated label no longer includes language indicating that the safety and efficacy of LUPKYNIS has not been established beyo...

hc-wainwright--co-reiterates-buy-on-aurinia-pharmaceuticals-maintains-13-price-target
HC Wainwright & Co. Reiterates Buy on Auri...
03/01/2024 19:09:24

HC Wainwright & Co. analyst Ed Arce reiterates Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Buy and maintains $13 price ...

aurinia-receives-exemptive-relief-from-canadian-securities-regulators-for-share-repurchase-program
Aurinia Receives Exemptive Relief from Can...
02/29/2024 14:10:15

cantor-fitzgerald-maintains-overweight-on-aurinia-pharmaceuticals-lowers-price-target-to-10
Cantor Fitzgerald Maintains Overweight on ...
02/23/2024 17:11:00

Cantor Fitzgerald analyst Olivia Brayer maintains Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Overweight and lowers the pri...

analog-devices-to-rally-around-19-here-are-10-top-analyst-forecasts-for-thursday
Analog Devices To Rally Around 19%? Here A...
02/22/2024 12:23:19

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

hc-wainwright--co-maintains-buy-on-aurinia-pharmaceuticals-lowers-price-target-to-13
HC Wainwright & Co. Maintains Buy on Aurin...
02/22/2024 11:44:19

HC Wainwright & Co. analyst Ed Arce maintains Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Buy and lowers the price targ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION